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Interferon gamma (IFN-y) induces human leukocyte antigen 
~HLA)-DR antigen expression on a variety of cell types, and 
~n human skin cells this induction is inhibited by trypsin 
mhibitors. Recently a trypsin-like protease was characterized 
w~ose activity is required for HLA-DR induction in a hybrid 
epidermal cell line. Glucocorticosteroids also inhibit IFN-y-
induced HLA-DR expression, and similarities have been 
noted between the inhibition by trypsin inhibitors and by 
~lucocorticosteroids. To assess the possibility that glucocor-
t~costeroid inhibition of IFN-y- induced HLA-DR expres-
Sion might be due to induction of an inhibitor of trypsin 
activity that is re-expression, we examined culture medium 
supernates (eM) of glucocorticosteroid-treated cells for 
HLA-DR_ and trypsin-inhibitory activities. 
I nterferon gamma (IFN-Y) induces human leukocyte antigen (HLA)-DR antigen expression on a variety of cell types, and in human skin cells this induction is inhibited by trypsin ~nhibitors [1] . Recently a trypsin-like protease was character-h . lzed whose activity is required for HLA-DR induction in a 
ybnd epidermal cell line [2]. Glucocorticosteroids also inhibit 
IFN-Y-induced HLA-DR expression, and similarities have been 
noted between the inhibition by trypsin inhibitors and by glucocor-
thcosteroids [1,3-5]. Because of these similariities we postulated 
t at glucocorticosteroid inhibition of IFN-y-induced HLA-DR 
expression might be due to induction of a trypsin inhibitor. To 
assess this possibility, we examined culture medium supernates 
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reVlatlons: 
BAPNA: Na-benzoyl-DL-arginine p-nitroanilide 
BGG: bovine gamma globulin 
BSA: bovine serum albumine 
CM: CUlture medium supernates 
FCS: fetal calf serum 
GGA-pNA: p-glu-gly-arg-p-nitroanilide 
HLA: human leukocyte antigen 
IFN_y: interferon gamma 
~WCO: molecular weight cutoff 
SiMI/BSA: RPMI 1640 plus 0.1 % bovine serum albumin 
M: serumfree medium 
TPCK: tosyl-L-phenylalanine chloromethyl ketone 
We report here that eM of glucocorticosteroid-treated 
H12 cells contain inhibitors of HLA-DR expression and of 
trypsin activity, but that the two inhibitors are not identical. 
H12 cells constitutively secrete a greater than 30,000 MW, 
acid- and heat-stable trypsin inhibitor, whose expression is 
not modulated by glucocorticosteroid or IFN-y, and that does 
not inhibit IFN-y- induced HLA-DR expression. The HLA-
DR inhibitor, on the other hand, is present only in eM of 
glucocorticosteroid-treated cells, is distinct from glucocorti-
costeroid itself, of a MW less than 500 and does not inhibit 
trypsin. We conclude, therefore, that the glucocorticosteroid 
inhibition of IFN-y- induced HLA-DR expression is by a 
mechanism other than secretion of a trypsin inhibitor.J Invest 
Dermatol 99:35 - 39, 1992 
(CM) of glucocorticosteroid-treated H12 cells, a hybrid human epi-
dermal cell line [1], for HLA-DR- and trypsin-inhibitory activities. 
We report here that CM of glucocorticosteroid-treated 12 cells 
contain inhibitors of HLA-DR expression and of trypsin activity, 
but that the two inhibitors are not identical. The trypsin inhibitor is 
constitutively expressed, present in CM of untreated as well as glu-
cocorticosteroid-treated cells, and is not involved in HLA-DR regu-
lation. The HLA-DR inhibitor, on the other hand, is present only in 
CM of glucocorticosteroid-treated cells, is distinct from glucocorti-
costeroid itself, and does not inhibit trypsin. We conclude, there-
fore, that the glucocorticosteroid inhibition of IFN-y-induced 
HLA-DR expression is by a mechanism other than secretion of a 
trypsin inhibitor. 
MATERIALS AND METHODS 
Materials Recombinant DNA-deriv..ed human IFN-y (2.7 X 107 
U/mg) was a gift from Genentech (South San Francisco, CA). 
Triamcinolone acetonide, dexamethasone, hydrocortisone, cortex-
olone, bovine serum albumine (BSA) fraction v, cycloheximide, 
Na-benzoyl-DL-arginine p-nitroanilide (BAPNA), p-glu-gly-arg-
pNA (GGA-pNA), N-tosyl-L-phenylalanine chloromethyl ketone 
(TPCK)-treated trypsin, and TPCK-treated trypsin-linked agarose 
were obtained from Sigma (St. Louis, MO). 3H-triamcinolone ace-
tonide (26 Ci/mmole) and 3H-dexamethasone (97 Cijmmole) 
were purchased from Amersham (Arlington Heights, IL), amcinon-
ide, a potent glucocorticosteroid, from Lederle Labs (Pearl River, 
NY), anti-dexamethasone sheep polyclonal antibody from Cam-
bridge Medical Diagnostics (Billerica, MA), and urokinase (human 
urine) from Calbiochem (San Diego, CA). 
Cell Culture H12 cells are a somatic cell hybrid between isolated 
normal human epidermal cells and HT-1080, a human fibrosar-
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coma cell line that is deficient in hypoxanthine guanine ribosyl 
transferase (6). 
Generation of Supernatant Culture Medium (CM) H12 
cells were grown to confluency in 100-mm dishes, washed three 
times with PBS, and initially incubated in RPMI containing 0.1 % 
bovine serum albumine (RPMI/BSA) with or without the addition 
of 103 U/ml IFN-y, 2 X 10-5 M glucocorticosteroid (~mcinonide, 
dexamethasone, triamcinolone acetonide, or hydrocortisone) or 10 
fl.g cycloheximide for 10 min, 2 h, or 4 h. The mediu.m was aspi.r-
ated, and the monolayers washed with PBS, and mcubated m 
RPMI/BSA for varying lengths of time. CM from control, un-
treated (control-CM), IFN-y-.treated .(IFN-CM), a~d glucocor-
ticosteroid-treated (glucocorticosterOid-CM, amcmomde-CM, 
triamcinolone acetonide-CM, dexamethasone-CM, hydrocorti-
sone-CM) cells were collected, centrifuged to remove floating cells, 
aliquoted, and either frozen at -20 · C, or assayed immediately for 
trypsin- and HLA-DR- inhibitory activities. In some cases, mono-
layers were reincubated with RPMI/BSA and CM collected agam at 
indicated intervals. Parallel dishes of identically treated cells were 
trypsinized and cell counts determined. No difference in cell num-
ber (approximately 107 cells/dIsh) between cell treatments was 
noted. In one experiment, cells were cultured in serum-free kerat-
inocyte growth medium (SFM, Gibco, Grand Island, NY) ~or 2 
weeks, then C-CM and amcinonide-CM made in SFM as descnbed. 
HLA-DR Assay For the study of modulation ofIFN-y-induced 
HLA-DR expression by glucocorticosteroid or CM, cells were 
grown to confluency in 24-well tissue-culture plat.es, and then in-
cubated for 24 h in the presence ofl03U /ml IFN-ym RPMI, RPMI 
containing 2 X 10- 5 M glucocorticosteroid, or RPM I plus CM 
(50% CM). Because CM contained 0.1 % BSA, all wells contained 
BSA to a final concentration of 0.1 %. When tested, other reagents 
were added just prior to IFN-y. Cell-surface ~LA-DR was ?etected 
by indirect immunoflu.orescence and quantitated as descn~ed [1). 
The statistical difference between means was calculated usmg the 
Student two-tailed t test, with probability values less than 0.05 
regarded as significant. 
Measurement of Trypsin, Urokinase, and Trypsin Inhibitor 
Activity Trypsin and urokinase activities were assayed by hydrol-
ysis of the p-nitroanilide substrates BAP~A an? GGA~pNA (7) 
with absorbance measured at 410 nm. For mhlbltion studies, 100-
900 fl.1 of CM was mixed with protease 5 min before addition of the 
substrate. Standard curves for substrate hydrolysis were made utiliz-
ing a non-reaction limiting amount of trypsin or urokinase, and 
varying the amount of substrate. Results are expressed as nmoles of 
substrate hydrolyzed or "percent trypsin." 
Measurement of Residual Glucocorticosteroid in CM The 
amount of residual glucocorticosteroid in CM was determined by 
radioactive 3H-triamcinolone acetonide tracer studies and by a dex-
amethasone (20% amcinonide cross-reactive) radioimmunoassay. 
Both tests yielded the same amounts of residual glucocorticosteroid 
after an initial exposure to 2 X 10-5 M glucocorticosteroid for 2 h: 
4 X 10-8 M in the 0-2-h glucocorticosteroid-CM, 1 X 10-8 M in 
the 2 - 5-h glucocorticosteroid-CM, and 4 X 10-9 M in the 5 - 22-h 
glucocorticosteroid-CM. Residual amcinonide never eX,ceeded 8 X 
10- 9 M by radioimmunoassay. Because CM were typically diluted 
to 50% with fresh culture medium when assayed for HLA-DR 
inhibition, the effect of adding amcinonide to RPMI and control-
CM at final concentrations of2 X 10-9 M and 5 X 10-9 M on IFN-y 
induction ofHLA-DR was assessed. In at least 12 separate determi-
nations, control-CM failed to inhibit IFN-y induction ofHLA-DR, 
whereas amcinonide-CM inhibited such induction by 40% (p < 
0.001). The addition of amcinonide (2 X 10- 9 M and 5 X 10-9 M) 
to RPMI or to control-CM failed to inhibit DR induction. There-
fore amcinonide at the concentration of residual amcinonide in 
amcinonide-CM, when assayed either in fresh RPMI alone or in 
control-CM, is incapable of producing the magnitude of inhibitions 
induced by amcinonide-CM. 
To further determine whether the HLA-DR inhibitor is not the 
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glucocorticosteroid, amcinonide itself, amcinonide-CM, and 
RPMI + amcinonide were treated with chloroform to extract am-
cinonide, and the aqueous phases assayed for inhibitory activities. In 
at least four separate experiments all of the HLA-DR inhibitory 
activity (i.e., amcinonide itself) is extracted from the aqueous phase 
of RPM I + amcinonide (2 X 10- M), but only 45% (p < 0.001) of 
the amcinonide-CM inhibitor is removed by chloroform. This sug-
gests that amcinonide induces the production ?f a :vater-so.luble 
inhibitor responsible for 55% of the HLA-DR-l11Iubltory actlVlty. 
Not unexpectedly, unlike interferon-inhibitory activity, chloro-
form extraction did not significantly reduce the amount of trypsm-
inhibitory activity in amcinonide-CM (Table II) . 
Furthermore, when cells are exposed to 2 X 10- 5 M cortexolone 
(a glucocorticosteroid antagonist that binds to the glucocorticoster-
oid receptor but has no glucocorticosteroid activity) prior to expo-
sure to amcinonide or amcinonide-CM, all (100%) of the amcinon-
ide-dependent, but virtually none (4%, non-significant) of the 
amcinonide-CM -dependent HLA-DR inhibition, is blocked. Simi-
larly, a combination of chloroform extraction followed by cortexo-
lone treatment, either of which alone blocks all of the inhibitory 
activity of amcinonide itself, failed to significantly reverse the am-
cinonide-CM HLA-DR inhibition over that of extracted amcinon-
ide-CM without cortexolone. 
Trypsin-Agarose Treatment of CM One milliliter agarose-
linked trypsin (80 NQ-benzoyl-I-arginine ethyl ester [BAEE) units 
trypsin/ml packed gel) suspended in RPMI (20 units trypsin/ml) 
and 10.0 ml of CM were mixed and stirred on ice for 30 min [8]. 
The mixture was then filtered through 0.2-fl.m filters and the fil-
trate assayed for trypsin- and HLA-DR-inhibitory activities. 
Heat and Acid Treatment of CM Amcillonide-CM or 
RPM I + amcinonide were either heated to 80 · C for 15 min, or 
acidified with 1 N HCI to pH 3.0 for 1 hat 37"C, followed by pH 
readjustment to 7.4, and assayed for ability to inhibit HLA-DR 
expression and trypsin activity. 
Ultrafiltration of CM To estimate and compare the sizes of the 
CM HLA-DR and trypsin inhibitors, amcinonide-CM and 
RPMI + amcinonide were subjected to ultrafiltration through 
30,000, 5,000, 1,000, or 500 molecular weight cutoff (MWCO) 
YMT membranes (Amicon Corp., Danvers, MA) . The ultrafiltrates 
were then assessed for inhibitory activities. 
RESULTS 
Inhibition ofHLA-DR induction. CM from control, IFN-y-
treated, and glucocorticosteroid-treated cells were examined for 
HLA-DR- and trypsin-inhibitory activities. H12 cells do not Con-
stitutively express significant levels of HLA-DR antigen, but are 
readily inducible by lFN-y. Following a 24-h exposure to 103 U 
IFN-y/ml approximately 50% ofH12 cells express indirect immu-
nofluorescent-detectable antigen (Table I) . Amcinonide, dexa-
methasone, and triamcinolone acetonide, but not hydrocortisone, a 
relatively weak glucocorticosteroid, significantly inhibit this induc-
tion. CM from glucocorticosteroid-treated cells, but not from con-
trol or IFN-y- treated cells, also inhibit the induction of HLA-DR 
on H12 cells (Table I). A 10-min exposure to 2 X 10- 5 M amcinon-
ide was not sufficient to generate inhibitory activity in the CM, but 
a 2-h or 4-h exposure resulted in significant inhibition. Amcinon-
ide-CM collected after incubation periods of 0 - 2 h, 2 - 5 h, and 
5 - 22 h following a 2-h preincubation with amcinonide were all 
equally inhibitory. The 0 -18-h amcinonide-CM were somewhat 
more inhibitory. Glucocorticosteroid-CM collected from cells that 
had been preincubated with dexamethasone or triamcinolone ace-
tonide also inhibited HLA-DR expression (Table I). However, CM 
from hydrocortisone-treated cells, as with hydrocortisone itself, 
were not inhibitory. 
Inhibition of Trypsin and Urokinase Activity CM were also 
assessed for the presence of trypsin inhibitors . Trypsin activity was 
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Table I. Inhibition by Glucocorticosteroids and CM of 
Interferon-y- Induced HLA-DR Antigen Expression on H 12 Cells' 
Percent DR + Cells ± SD Percent IFN-y 
IFN-y IFN-y Plus Induction of DR 
Agent (10 3 V/ml) Agent (p<) 
Amcinonide 48 ± 12 22 ± 9 44 (0.001) 
Dexamethasone 47 ± 10 48 ± 12 60 (0.05) 
Triamcinolone 57 ± 5 36 ± 11 63 (0.01) 
Hydrocortisone 50 ± 11 38 ± 5 75 (NS) 
Control-CM 50 ± 11 46 ± 10 91 (NS) 
Interferon-CM 66 ± 3 60 ± 10 92 (NS) 
Amcinonide-CM 50 ± 11 30 ± 11 60 (0.001) 
Dexamethasone-CM 47 ± 10 27 ± 10 57 (0.05) 
Triamcinolone 47 ± 10 24 ± 3 51 (0.05) 
acetonide-CM 
Hydrocortisone-CM 47 ± 10 24± 3 85 (NS) 
• In a total volume of 1.0 ml, confluent H 12 cell monolayers in 24-well tissue-culture 
lates were incubated 24 h in RPM I containing 103 Ulml IFN-y in the presence or 
;bsence of 2 X IO-s M amcinonide, dexamethasone, triamcin~lo.ne acetonide, or hy-
d ocortisone or 50% CM (CM + RPMI 1: 1). Cells were trypmuzed and stamed, and t~e percentage of HLA-DR ~ositive cell s deter~in."d. Values represent the mean ± 
tandard deviation of at least SIX separate determmatlons. CM was generated by prem-
s bating H 12 cell mono layers with or without IFN-y or glucocorticosteroid for 2 h, 
::ashing mono layers, replenishing with RPMI, and collecting after two additional 
hours of incubation at 37'C. 
measured by a colorimetric amidolytic assay, using BAPN A as a 
substrate and TPCK-trypsin as standard. There is abundant tl)'psin 
inhibitor in H12 cell 0-18 h CM (Table II) . However, no differ-
ence in the amount of inhibitor could be detected between CM from 
control, IFN-y-treated, or glucocorticosteroid-treated cells, and 
therefore appears to be constitutively produced, with 1 ml of CM 
capable of inhibiting approximately 0.5 units trypsin. Control-CM, 
lFN-eM, and amcinonide-CM were also assayed for urokinase in-
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hibitory activity using GGA-pNA as substrate but none were inhibi-
tory. 
Characterization of HLA-DR and Trypsin Inhibitors Be-
cause the HLA-DR inhibitor is found only in CM from glucocorti-
costeroid-treated cells, it seemed unlikely that the CM HLA-DR 
inhibitor and the CM-trypsin inhibitor were identical. Further-
more, we determined that the HLA-DR inhibition was not merely 
due to residual glucocorticosteroid (see Materia ls and Methods) and 
that the trypsin inhibitor is not fetal calf serum - derived. 
The H12 cell amcinonide-CM HLA-DR and trypsin inhibitors 
were further compared for heat and acid stability, abi lity to bind 
trypsin, and size. Both amcinonide-CM inhibitory activities, as well 
as amcinonide itself, were found to be acid stable (PH 3.0 for 1 h) 
and insignificantly affected by, heating to 80·C for 15 min (Tables 
II and III) . CM were exposed to trypsin-linked agarose in an attempt 
to affinity bind the trypsin inhibitor. After removal of the agarose by 
filtration, the CM filtrate was assayed for inhibitory activities. As 
expected, none of the HLA-DR inhibitor, but all of the trypsin 
inhibitor was removed from the amcinonide-CM by trypsin-agar-
ose binding. To compare the sizes of the inhibitors, amcinonide-
CM were subjected to ultrafiltration through 30,000, 5,000,1,000, 
and 500 MWCO filters, and the fi ltrates compared to unfiltered 
CM. None of the HLA-DR inhibitor was removed by even the 500 
MWCO filter, whereas all of the trypsin inhibitor was removed by 
the 30,000 MWCO filter (Tables II and III). 
Because cultured cells are known to ingest the FCS-derived tryp-
sin inhibitor fetuin, and later re-release it in active form into serum-
free culture medium [9]' the origin of the H12 cell CMtrypsin 
inhibitor was studied. H12 cells were cultured in SFM for 2 weeks, 
after which control-cell CM were assayed for the presence of tryp-
sin inhibitor. Although H12 cells did not grow as rapidly in SFM as 
in RPMIjBSA, there was considerable trypsin inhibitor present in 
the SFM-CM. Nine hundred microliters of SFM-CM (0-18 h) 
inhibited 1.2 units trypsin by 47% (p < 0.001), compared to 59% 
Table II. Inhibition of Trypsin Activity by CM· 
Trypsin Assay 
Trypsin Activiry 
Bapna Percent Inhibition 
Buffer Hydrolyzed Percent Reversed 
Buffer Treatment (nmoles) Control by Treatment 
RPMI 96 ± 41 100 
C-CM 34 ± 11 356 
IFN-CM 31 ± 12 336 
AM-CM 28 ± 16 296 
RPMI 96 ± 41 100 
AM-CM 32 ± 21 34' 
AM-CM 15 min, 80 ' C 39 ± 16 42' 12 
RPMI 66 ± 16 100 
AM-CM 23 ± 8 34J 
AM-CM 1 h. pH 3.0, 37'C 21 ± 3 32' 0 
RPMI 82± 8 100 
AM-CM 34 ± 5 426 
AM-CM Chloroform extraction 45 ± 10 51 ' 16 
RPMI 86 ± 17 100 
AM-CM 31 ± 3 36' 
AM-CM < 30,000 MW fi ltrate 94 ± 8 109 100' 
RPMI 92±6 100 
AM-CM 63 ± 16 69J 
AM-CM Trypsin-agarose 100 ± 13 109 100' 
• CM were treated with heat, acid, chloroform, trypsin-agarose, or ultrafi ltration as described in Material a .. d Methods. In a total volume of 1200 pI, 900 pI of CM (500 pI for the 
trypsin-agarose treatment) were mixed with 0.6 BABE units trypsin 5 min before addition of substrate. Values represent nmoles BAPNA hydrolyzed after 3 h at 37 ' C (mean ± 
standard deviation of at least two separate determinations). Control (C)-CM and IFN-CM, as well as RPMI, were also treated and assayed. There were no significant differences 
between C-CM, IFN-CM, and amcinonide (AM)-CM values, or between treated and untreated RPM!. Therefore, only untreated RPMI and treated amcinonide-CM values are 
reported. 
I p < 0.001 compared to RPMI values. 
, p < 0.001 compared to RPM! values. 
, p < 0.05 compared to RPM I values. 
, p < 0.05 compared to untreated amcinonide-CM values. 
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Table III. Effects of Heat, Ultrafiltration, and Trypsin-Agarose 
Treatments of Amcinonide and Amcinonide-CM Inhibition of 
IFN-y- Induced HLA-DR Expression ofH12 Cellsa 
Percent Percent 
DR + Cells IFN-y-
IFN-y Induced 
Culture Medium Treatment (10 3 U/ml) DR 
Amcinonide-CM 26 ± 11 52 
Amcinonide-CM 15 min, 80°C 41 ± 10 41 
RPM I 66 ± 3 100 
RPMI 60 min, pH 3.0, 37"C 62 ± 4 94 
Amcinonide-CM 34 ± 1 51 
Amcinonide-CM 60 min, pH 3.0, 37°C 30 ± 11 46 
RPMI 52 ± 9 100 
RPMI 500 MWCO filtrate 42 ± 1 81 
RPMI + Amcinonide 31 ± 3 60 
RPMI + Amcinonide 500 MWCO filtrate 25 ± 2 48 
Amcinonide-CM 34 ± 16 65 
Amcinonide-CM 500 MWCO filtrate 34 ± 14 65 
RPMI 48 ± 13 100 
Amcinonide-CM 17 ± 9 35 
Amcinonide-CM Trypsin-agarose 17 ± 8 35 
• RPMI, RPMI + amcinonide, or amcinonide-CM were treated with either heat. 
acid. or trypsin-agarose. or ultrafi ltered, as described. Cells were incubated overnight in 
500 III RPMI containing 10' Ulml IFN-y plus 500 III treated or untreated RPMI. 
RPM I + amcinonide, or amcinonide-CM and harvested. and the percentage of HLA-
DR positive cell s determined. Values reported represent the mean ± SD of at least two 
separate determinations. 
(p < 0.05) inhibition by CM from FCS-grown cells. Furthermore, 
when cells were preincubated in RPMIjBSA containing 10 .ugjml 
cycloheximide, the amount of trypsin inhibitor present in CM was 
reduced by 59%, indicating its cellular origin. Unlike its inhihibory 
action on production of the trypsin inhibitor, cycloheximide did not 
inhibit production of the inhibitor of IFN-y induction ofHLA-DR 
expression, with a 40% inhibition ofIFN-y- induced HLA-DR and 
45% inhibition by cycloheximide + amcinonide-CM in the pres-
ence of cycloheximide. 
DISCUSSION 
IFN-y-induced HLA-DR antigen expression in human skin cells 
requires the activity of a trypsin-like protease, and is inhibited by 
glucocorticosteroids and trypsin inhibitors [1,2] . Because glucocor-
ticosteroids are known to down-regulate serine protease activity by 
induction of inhibitors as well as inhibition of protease production 
[3 -5.10-14], and the similarity between the inhibitions ofHLA-
DR expression by glucocorticosteroids and trypsin inhibitors, we 
addressed the possibility that the glucocorticosteroid inhibition 
might be the result of induction of a secreted trypsin inhibitor. 
However, although we have shown that glucocorticosteroid do 
induce secretion of an HLA-DR inhibitor in H12 cells, that inhibi-
tor does not also inhibit trypsin activity. In addition, H12 cells 
constitutively secrete a trypsin inhibitor whose expression is not 
altered by cell treatment with IFN-y or glucocorticosteroid, and 
that does not modulate HLA-DR expression. The glucocorticoster-
oid-inducible HLA-DR inhibitor is a small, partially water soluble, 
acid- and heat-stable molecule whose expression is not blocked by 
cycloheximide. The trypsin inhibitor is a large, heat- and acid-stable 
molecule, whose expression is blocked by cycloheximide. 
A 10-min cellular preincubation with amcinonide was not suffi-
cient to induce CM HLA-DR inhibitory activity . A 2- or 4-h prein-
cubation, however, resulted in significant inhibitory activity, with 
approximately the same amount of inhibitor secreted within the 
first 2 h as in hours 5 through 22 (data not shown). In contrast, the 
amount of trypsin inhibitor in CM collected at the various time 
points approximately paralleled the time of culture medium cell 
exposure. 
Although the size of the HLA-DR inhibitor (MW < 500) is 
similar to that of glucocorticosteroid itself (MW amcinonide = 
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502), several lines of evidence contradict the possibility that the 
inhibitor is glucocorticosteroid itself. First, glucocorticosteroid are 
100% soluble in chloroform, whereas the HLA-DR inhibitor is 
55% water soluble. Second, inhibition of HLA-DR expression by 
amcinonide is completely blocked by the glucocorticosteroid antag-
onist cortexolone, whereas usually none of the amcinonide-CM 
HLA-DR inhibitor is blocked. Third, the amount of residual gluco-
corticosteroid in glucocorticosteroid-CM measured by RIA and 
tracer studies, when assayed in either RPMI alone or in C-CM, do 
not inhibit HLA-DR induction to the same extent as amcinonide-
CM itself. In human cells, nucleotides are released from cells under 
physiologic and pathologic conditions and exert immunoregulatory 
effects via external receptors [15 - 20]. In light of the size and solu-
bility characteristics of the H12 cell, CM HLA-DR inhibitor raise 
the possibility that the inhibitor could be a nucleotide . 
The H12 trypsin inhibitor (MW > 30,000) appears to be differ-
ent from other previously described secreted trypsin inhibitors. It 
does not seem likely that it is the FCS-derived trypsin inhibitor 
feruin (MW 47,000) known to be ingested by cultured cells and 
released in active form into serum free culture medium up to a week 
later [9]. First, fetuin is acid labile, whereas the H12 trypsin inhibi-
tOr is acid stable [9]. In addition, the fact that expression of the H12 
trypsin inhibitor is reduced 60% in the presence of cycloheximide 
and that it is still produced in significant quantities after 2 weeks of 
ceil growth in SFM strongly suggests that it is an H12 cellular 
product. HTI080 human fibrosarcoma cells, one of the parents of 
hybrid H12 cells, secrete a large (MW 54,000) urokinase inhibitor 
[21]. However, we failed to detect any urokinase inhibitory activity 
at all in H 12 cell CM. Anchorage-dependent cells, including fibro-
bla.sts, heart muscle cells, and kidney epithelial cells, secrete protease 
ne:xin (MW 43,000), an acid labile inhibitor of trypsin, urokinase, 
thrombin, and plasmin [22,23] . However, again, the H12 cell inhib-
itor is acid stable and does not inhibit urokinase. Kazal type trypsin 
inhibitors, produced mainly by tumor cells and the pancreas, like 
the H12 inhibitor, are poor inhibitors of urokinase, but are too small 
(MW 6200) to be considered as being related to the H 12 inhibitor 
[24]. 
It is well established that normal human keratinocytes are in-
duced to express HLA-DR in response to either in vitro or in vivo 
exposure to IFN-y [25]. It is unknown whether the inhibitor of 
IFN-y produced by human H12 cells (somatic hybrids of epidermal 
and HT1080 cells) in response to exposure to glucocorticosteroid is 
also elaborated by keratinocytes treated similarly. 
In summary, we have described the secretion of a small, water-so-
luble HLA-DR inhibitor by H 12 hybrid epidermal cells in response 
to glucocorticosteroid, which does not also inhibit trypsin activity, 
and is distinct from glucocorticosteroid itself. H12 cells also consti-
tutively secrete a large, acid- and heat-stable trypsin inhibitor, 
whose expression is not modulated by glucocorticosteroid or IFN-y, 
and that does not inhibit IFN-y-induced HLA-DR expression. 
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ANNOUNCEMENT 
A French-Polish dermatologic meeting will take place in Warsaw on September 11-14, 1993. 
Lectures, patient viewing sessions, case reports, and other free communications are planned. 
The official languages are French and English. 
For information contact the scientific organizers, Pr. S. Jablonska and J. Thivolet at pavilion 
R, H6pital Edouard Herriot, 69437 Lyon, France (Tel, F-78 5471 16: fax, F-72 33 7131) or 
Department of Dermatology, Koszykowa B2A, 02008 Warszawa, Poland [Tel, PL-(22)21 51 
80j. 
